In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .
Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study.
OBJECTIVE To report results from a long-term prospect i ve study of safety of haloperidol treatment and prevalence of haloperidol-related dyskinesias . METHOD Subjects were children with autism requiring pharmacotherapy for target symptoms . After baseline assessment s , children received haloperidol treatment ; responders requiring further treatment were considered for enrollment into the present study . Six-month haloperidol treatment periods were followed by a 4-week placebo period . The procedure was repeated if further haloperidol treatment was required . At specified times children were evaluated by using multiple instruments . RESULTS Between 1979 and 1994 , 118 children aged 2.3 to 8.2 years participated in the study . The mean dose of haloperidol was 1.75 mg/day . Mainly withdrawal dyskinesias ( WD ) developed in 40 ( 33.9 % ) children ; 20 had more than one dyskinetic episode . A subgroup that remained significantly longer in the study and had a significantly higher cumulative dose of haloperidol evidence d a significantly higher incidence of WD . Occurrence rates of tardive dyskinesia ( TD ) and multiple episodes of TD/WD were higher among girls . CONCLUSION Female gender and pre- and perinatal complications may be involved in susceptibility to dyskinesias ; greater cumulative haloperidol dose and /or longer exposure to haloperidol may increase the risk
In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .